1-5 of 5
Sasha Sreckovic
Close
Sort by
Journal Articles

Two Currently Recruiting Randomized Phase III Trials: COMMODORE 1 and 2 Evaluating Crovalimab Vs Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Current Anti-Complement Therapy

Austin G. Kulasekararaj, Antonio Risitano, Alexander Roeth, Guangsheng He, Jeffrey Pu, Lilyan Wright, Anita Appius, Alexandre Sostelly, Sasha Sreckovic, Sven F Stanzel, Talha Munir, Jun-Ichi Nishimura
Journal: Blood
Blood (2021) 138 (Supplement 1): 4313.
https://doi.org/10.1182/blood-2021-152306
Published: 2021
Journal Articles

Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 1 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Complement Inhibitors

Antonio Risitano, Alexander Röth, MD, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Jeffrey Pu, MDPhD, Jun-ichi Nishimura, MD PhD, Lilyan Wright, PhD, Anita Appius, PhD, Alexandre Sostelly, PhD, Sasha Sreckovic, MD, Charlotte Vignal, PhD, Talha Munir, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-137471
Published: 2020
Journal Articles

An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial

Jun-ichi Nishimura, MD PhD, Antoine Soubret, PhD, Simon Buatois, PharmD, PhD, Jean-Eric Charoin, Sasha Sreckovic, MD, Christoph Bucher, Jules Hernández-Sánchez, PhD, Gregor Jordan, Julia Ramos, MD PhD, Noriko Arase, MD PhD, Masaki Hotta, Yoshitaka Isaka, Yoshikazu Ito, MD PhD, Yuzuru Kanakura, MD PhD, Jin Seok Kim, MD PhD, Taroh Kinoshita, PhD, Eiichi Morii, Jens Panse, MD, Regis Peffault De Latour, MD PhD, Alexander Röth, MD, Hubert Schrezenmeier, Simona Sica, MD PhD, Hiroyuki Takamori, MD, Yasutaka Ueda, Sung-Soo Yoon, MD PhD, Ido Paz-Priel, Alexandre Sostelly, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-136265
Published: 2020
Journal Articles

Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 2 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Not Previously Treated with Complement Inhibitors

Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Guangsheng He, MD PhD, Talha Munir, MBBS, Jeffrey Pu, MDPhD, Antonio Risitano, Alexander Röth, MD, Camelia S. Sima, MD, Anita Appius, PhD, Alexandre Sostelly, PhD, Sasha Sreckovic, MD, Charlotte Vignal, PhD, Jun-Ichi Nishimura, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 34.
https://doi.org/10.1182/blood-2020-136647
Published: 2020
Journal Articles

COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria

Regis Peffault De Latour, MD PhD, Simona Sica, MD PhD, Julia Ramos, MD, Jules Hernández-Sánchez, PhD, Jin Seok Kim, MD PhD, Anna Kiialainen, PhD, Sung-Soo Yoon, MD PhD, Sasha Sreckovic, MD, Antoine Soubret, PhD, Haruhiko Ninomiya, MD PhD, Alexandre Sostelly, PhD, Jens Panse, MD, Simon Buatois, PharmD, PhD, Hubert Schrezenmeier, Ido Paz-Priel, MD, Jun-ichi Nishimura, MD PhD, Alexander Röth, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–7.
https://doi.org/10.1182/blood-2020-135841
Published: 2020